1 Min Read
June 12 (Reuters) - HERANTIS PHARMA OYJ:
* HERANTIS PHARMA‘S CLINICAL STUDY WITH CDNF IN PARKINSON‘S DISEASE AUTHORIZED IN FINLAND, COMPANY EXPANDS ON DEVELOPMENT PLAN Source text for Eikon: Further company coverage: (Gdynia Newsroom)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.